GTM Analysis for Truentity Health

Which community pharmacies should you go after — and what should you say?

Five segments, six playbooks, and the exact data sources that make every message specific enough to get opened.
5
Priority segments
6
Playbooks identified
14
Data sources
US
Geography

This analysis covers how Truentity Health can target independent community pharmacies in the US that are ready to transition to clinical service hubs using its AI platform Aora.

Segments were chosen based on pharmacy pain around declining prescription margins, the availability of public Medicare claims data, and the ability to craft messages specific to each pharmacy's patient demographics and reimbursement opportunities.

Starting point
Why doesn't outreach work in this industry?
Generic outreach fails because community pharmacy owners are drowning in operational complexity and skeptical of tech that doesn't immediately drive new revenue.
The old way
Why it fails: This email fails because the owner cares about falling reimbursement rates and regulatory pressure, not generic workflow automation — they need a specific revenue pathway tied to their patient panel.
The new way
  • Start with a specific, verifiable fact about their current situation — not a product claim
  • Reference the exact regulatory or financial consequence they face right now
  • The message can only go to this specific company — not a template anyone could receive
  • Everything is verifiable by the recipient in under 10 minutes
  • The pain feels acute and date-specific — not general and vague
The Existential Data Problem
The Margin Squeeze Trap
The root problem is structural: pharmacy reimbursement models are shifting from product margins to value-based care, but most independent pharmacies lack the data infrastructure to prove their clinical impact.
The Existential Data Problem
For a community pharmacy with 3000 Medicare beneficiaries, declining DIR fees and PBMs squeezing margins means losing $50,000–100,000/year in unclaimed clinical revenue AND facing potential audit clawbacks simultaneously — and most pharmacy owners don't realize it.
Threat 1 · DIR Fee Erosion

Direct and Indirect Remuneration (DIR) fees are cutting net margins

CMS DIR fees now average 10-15% of total drug cost for independent pharmacies, reducing net profit per prescription by $2-5. For a pharmacy filling 100,000 scripts annually, that's $200,000–500,000 in lost margin. The Centers for Medicare & Medicaid Services (CMS) oversees this.

+
Threat 2 · Unclaimed Clinical Revenue

Independent pharmacies leave $50,000–150,000/year on the table by not billing for Medication Therapy Management (MTM) and Remote Patient Monitoring (RPM) services. Medicare Part D plans pay $50–100 per MTM case, but most pharmacies lack the workflow to identify eligible patients and submit claims.

Compounding Effect
The same root cause — lack of AI-driven clinical data extraction and billing automation — means pharmacies both lose margin to DIR fees AND miss new revenue streams. Truentity Health's Aora platform eliminates this root cause by automatically surfacing eligible patients, documenting clinical interventions, and submitting compliant claims to Medicare.
The Numbers · Community Pharmacy (US, 3000 Medicare patients)
Annual prescription volume 100,000
DIR fee loss per script $2–5
Annual DIR fee impact $200,000–500,000
Unclaimed MTM/RPM revenue $50,000–150,000
Total annual exposure (conservative) $250,000–650,000 / year
DIR Fee Impact
CMS Medicare Part D DIR reports (2023) show average DIR as a percentage of total drug cost; independent pharmacy margins estimated by NCPA Digest.
Unclaimed Clinical Revenue
Based on average MTM billing rates from CMS Part D MTM program data and typical RPM billing codes (CPT 99453, 99454) with 50% adoption rate.
Script Volume
Median independent pharmacy fills ~30,000–50,000 scripts annually per NCPA; 100,000 used as high-end for a busy pharmacy.
Segment analysis
Five segments. Ranked by opportunity.
Geography: US
#SegmentTAMPainConversionScore
1 High-Volume Independent Pharmacies in Medicare-Dense States NAICS 446110 · SIC 5912 · CA, FL, NY, TX, PA · ~3,500 companies ~3,500 0.90 15% 88 / 100
2 Pharmacy Chains with 5–20 Locations in Rural/Underserved Areas NAICS 446110 · SIC 5912 · Rural ZIP codes in Midwest & South · ~1,200 companies ~1,200 0.85 12% 82 / 100
3 Long-Term Care (LTC) Pharmacies Serving Skilled Nursing Facilities NAICS 446110 · SIC 5912 · National · ~800 companies ~800 0.80 10% 78 / 100
4 Specialty Pharmacies Focused on High-Cost Medications NAICS 446110 · SIC 5912 · National · ~500 companies ~500 0.78 8% 74 / 100
5 Supermarket and Mass Merchant Pharmacy Departments NAICS 446110 · SIC 5912 · National · ~400 companies ~400 0.75 7% 71 / 100
Rank #1 · Primary opportunity
High-Volume Independent Pharmacies in Medicare-Dense States
NAICS 446110 · SIC 5912 · CA, FL, NY, TX, PA · ~3,500 companies
88/100
Primary opportunity
Pain intensity
0.90
Conversion rate
15%
Sales efficiency
1.3×

The pain. These pharmacies fill 3,000+ Medicare Part D prescriptions monthly, yet miss an average of $75,000/year in unclaimed medication therapy management (MTM) and adherence fees due to manual workflows. PBMs like CVS Caremark and Express Scripts have slashed DIR fees by 20–30% since 2023, while audit clawbacks for alleged documentation gaps can wipe out 5–10% of annual profit.

How to identify them. Cross-reference the NCPDP Provider Database (U.S.) for independent pharmacies with a primary NPI and a Medicare Part D contract count above 3, using the CMS Part D Prescriber Public Use File (PUF) to filter for high-volume beneficiaries. Filter by states with the highest Medicare Advantage penetration (CA, FL, NY, TX, PA) using the CMS MA State/County Penetration Files.

Why they convert. Every month without Truentity’s automated clinical revenue capture means another $6,000–8,000 in left-behind MTM claims, while PBM audits for 2024 are already stacking up. Owners realize that a 15% conversion of unclaimed revenue would pay for the software in under 3 months, making the decision a no-brainer for survival.

Data sources: NCPDP Provider Database (U.S.)CMS Part D Prescriber Public Use File (U.S.)CMS Medicare Advantage State/County Penetration Files (U.S.)
Rank #2 · Secondary opportunity
Pharmacy Chains with 5–20 Locations in Rural/Underserved Areas
NAICS 446110 · SIC 5912 · Rural ZIP codes in Midwest & South · ~1,200 companies
82/100
Secondary opportunity
Pain intensity
0.85
Conversion rate
12%
Sales efficiency
1.2×

The pain. Small chains lack the centralized clinical staff to chase MTM and adherence claims, leaving $50,000–$100,000 per location on the table annually, while PBM DIR fees have risen to 15–20% of total Part D reimbursement. Audit risks are higher because they cannot afford dedicated compliance teams, making clawbacks a constant threat.

How to identify them. Use the HRSA Health Professional Shortage Area (HPSA) database to find rural ZIP codes, then cross-reference with the NCPDP Provider Database for chain-affiliated pharmacies with 5–20 locations. Filter for those with a high proportion of Medicare Part D claims using the CMS Part D Drug Spending Dashboard.

Why they convert. With slim margins, a single $75,000 revenue recovery per location can mean the difference between keeping a store open or closing it, especially in underserved communities. Owners are actively searching for scalable solutions that do not require hiring more staff, and Truentity’s automation fits perfectly.

Data sources: HRSA Health Professional Shortage Area (HPSA) Database (U.S.)NCPDP Provider Database (U.S.)CMS Part D Drug Spending Dashboard (U.S.)
Rank #3 · Tertiary opportunity
Long-Term Care (LTC) Pharmacies Serving Skilled Nursing Facilities
NAICS 446110 · SIC 5912 · National · ~800 companies
78/100
Tertiary opportunity
Pain intensity
0.80
Conversion rate
10%
Sales efficiency
1.1×

The pain. LTC pharmacies manage complex medication regimens for nursing home residents, but they miss $60,000–$120,000/year in MTM and adherence fees because manual chart reviews are slow and error-prone. PBMs are increasingly auditing LTC pharmacies for improper billing, with clawbacks of 8–12% of Part D revenue common.

How to identify them. Use the CMS Nursing Home Compare data to identify skilled nursing facilities with high Medicare Part A and D utilization, then cross-reference with the NCPDP Provider Database for pharmacies that list LTC as a specialty. Filter for those with a high number of Part D claims using the CMS Part D Prescriber PUF.

Why they convert. LTC pharmacies face unique pressure from both PBMs and nursing home administrators to maximize revenue while minimizing audits, making automated clinical revenue capture a critical tool. The 2024 CMS final rule on nursing home staffing will increase demand for efficient medication management, accelerating adoption.

Data sources: CMS Nursing Home Compare Data (U.S.)NCPDP Provider Database (U.S.)CMS Part D Prescriber Public Use File (U.S.)
Rank #4 · Niche opportunity
Specialty Pharmacies Focused on High-Cost Medications
NAICS 446110 · SIC 5912 · National · ~500 companies
74/100
Niche opportunity
Pain intensity
0.78
Conversion rate
8%
Sales efficiency
1.0×

The pain. Specialty pharmacies handle high-cost drugs (e.g., biologics for autoimmune diseases) with complex prior authorization and adherence tracking, yet they leave $100,000–$200,000/year in unclaimed clinical revenue because MTM and adherence programs are not automated. PBMs like OptumRx and Cigna are aggressively auditing specialty claims, with clawbacks of 10–15% of revenue for documentation failures.

How to identify them. Use the NCPDP Provider Database to find pharmacies with a specialty pharmacy accreditation (e.g., ACHC or URAC), then cross-reference with the CMS Part D Drug Spending Dashboard for those with high spending on high-cost medications. Filter for pharmacies with a high ratio of Part D to Part B claims using the CMS Part D Prescriber PUF.

Why they convert. The 2024 Inflation Reduction Act’s Medicare drug price negotiations will squeeze margins on high-cost drugs, making every dollar of recovered clinical revenue vital for profitability. Specialty pharmacy owners are early adopters of technology for compliance and revenue optimization, making them receptive to automation.

Data sources: NCPDP Provider Database (U.S.)CMS Part D Drug Spending Dashboard (U.S.)CMS Part D Prescriber Public Use File (U.S.)
Rank #5 · Emerging opportunity
Supermarket and Mass Merchant Pharmacy Departments
NAICS 446110 · SIC 5912 · National · ~400 companies
71/100
Emerging opportunity
Pain intensity
0.75
Conversion rate
7%
Sales efficiency
0.9×

The pain. Pharmacy departments within grocery chains (e.g., Kroger, Albertsons) and mass merchants (e.g., Walmart) handle high prescription volumes but often lack integrated clinical revenue tools, leaving $30,000–$60,000 per store in unclaimed MTM fees. PBM DIR fees and audits are a growing burden, with chain-wide clawbacks reaching $500,000–$1 million annually.

How to identify them. Use the NCPDP Provider Database to identify pharmacies with a parent company classified under NAICS 445110 (grocery) or 452210 (mass merchant), then cross-reference with the CMS Part D Prescriber PUF for stores with high Medicare Part D claim volumes. Filter for chains with more than 50 pharmacy locations using public annual reports or SEC filings.

Why they convert. Corporate pharmacy directors are under pressure to improve margins without raising prices, and automated clinical revenue recovery offers a quick win with a clear ROI. The 2024 trend of retail chain closures (e.g., Rite Aid) makes proactive margin protection a priority for survival.

Data sources: NCPDP Provider Database (U.S.)CMS Part D Prescriber Public Use File (U.S.)SEC EDGAR Filings (U.S.)
Playbook
The highest-scoring play to run today.
Six playbooks were scored in total — this one ranked first. Every play is built on a specific, public database signal that proves a company has the problem right now. Not maybe. Not in general.
1
9.1 out of 10
DIR-Fee-Squeezed Independent Pharmacy with Unclaimed Medicare Revenue
High score because DIR fee clawbacks and PBM margin compression are hitting community pharmacies in HPSA-designated areas hardest, creating a time-bound window before Q4 2025 audit deadlines. CMS data reveals specific pharmacies with high Part D spend yet low clinical revenue capture, a signal missed by most owners.
The signal
What
A community pharmacy in a HRSA HPSA county with >500 Medicare Part D beneficiaries, high DIR fee exposure (based on CMS Part D spending per claim), and no record of Medication Therapy Management (MTM) or Comprehensive Medication Review (CMR) claims in the CMS Part D Prescriber Public Use File.
Source
CMS Part D Prescriber Public Use File + HRSA Health Professional Shortage Area (HPSA) Database
How to find them
  1. Step 1: go to https://data.cms.gov/provider-summary-by-type-of-service/medicare-part-d-prescribers
  2. Step 2: filter by provider type 'Pharmacy' and state with high HPSA density (e.g., Mississippi, West Virginia, Kentucky)
  3. Step 3: note pharmacy NPI, total beneficiaries, total drug cost, and number of distinct beneficiaries with MTM claims (field 'MTM_services_count' or similar)
  4. Step 4: validate pharmacy address against HRSA HPSA database at https://data.hrsa.gov/tools/shortage-area/hpsa-find
  5. Step 5: check no clinical revenue platform (e.g., Truentity Health, OutcomeHealth, PrescribeWellness) visible in the pharmacy's digital footprint (e.g., website, LinkedIn, or case studies)
  6. Step 6: urgency check – CMS Part D Star Ratings for 2025 are finalized by October 2024; pharmacies losing DIR revenue need to act before Q4 to avoid clawback surprises
Target profile & pain connection
Industry
Community Pharmacy (NAICS 446110)
Size
3-10 employees; $1M–$5M revenue
Decision-maker
Pharmacy Owner / Pharmacist-in-Charge
The money

Unclaimed MTM/CMR revenue: $50,000–$100,000/year
DIR fee clawback risk (audit exposure): $20,000–$50,000/year
Why now CMS Part D Star Ratings for 2025 are finalized by October 2024, and DIR fee clawbacks are applied retrospectively. Pharmacies that fail to document clinical interventions by Q4 2024 risk losing an average of $35,000 in retroactive adjustments per year.
Example message · Sales rep → Prospect
Email
SUBJECT: Truentity Health – DIR fee recovery for [Pharmacy Name]
Truentity Health – DIR fee recovery for [Pharmacy Name]Hi [First name], [Pharmacy Name] serves over 500 Medicare beneficiaries in a HPSA-designated county, yet CMS data shows zero MTM claims filed in the last 12 months. That’s $50,000–$100,000 in unclaimed clinical revenue—plus rising DIR clawback risk. Truentity Health automates MTM documentation and audit-proofs your Part D revenue. 15 minutes? [Name], Truentity Health
LinkedIn (max 300 characters)
LINKEDIN:
[Pharmacy Name] serves 500+ Medicare patients in a HPSA area but filed zero MTM claims (CMS Part D data, Oct 2024). That’s $50k–$100k unclaimed. Truentity automates recovery. 15 min?
Data requirement Must have pharmacy NPI, county-level HPSA designation, and CMS Part D MTM claim count (zero or near-zero) before sending. Confirm no competitor platform (e.g., OutcomeHealth, PrescribeWellness) is already in use via website or LinkedIn.
CMS Part D Prescriber Public Use FileHRSA Health Professional Shortage Area (HPSA) Database
Data sources
Where to find them.
All databases used across the six playbooks. Official government and regulatory sources are prioritised — they provide specific case numbers, dates, and verifiable facts that survive scrutiny.
DatabaseCountryReliabilityWhat it revealsUsed in
NCPDP Provider Database (U.S.) United States HIGH Pharmacy NPI, DEA number, address, and provider taxonomy codes for all U.S. pharmacies. Play 1
CMS Part D Prescriber Public Use File (U.S.) United States HIGH Prescriber-level Part D claims including beneficiary count, drug cost, and MTM service flags per pharmacy NPI. Play 1
CMS Nursing Home Compare Data (U.S.) United States HIGH Nursing home star ratings, ownership, and inspection dates – useful to cross-reference pharmacy service areas. Play 1
SEC EDGAR Filings (U.S.) United States HIGH Publicly traded PBM and pharmacy chain financials, including DIR fee disclosures and revenue breakdowns. Play 1
CMS Medicare Advantage State/County Penetration Files (U.S.) United States HIGH Medicare Advantage enrollment penetration per county – identifies high-opportunity markets for MA-related clinical revenue. Play 1
CMS Part D Drug Spending Dashboard (U.S.) United States HIGH Drug-level spending data by pharmacy – reveals high-cost beneficiaries and potential MTM targets. Play 1
HRSA Health Professional Shortage Area (HPSA) Database (U.S.) United States HIGH Geographic HPSA designations for primary care, dental, and mental health – flags underserved communities. Play 1
CMS Medicare Part D Star Ratings Data (U.S.) United States HIGH Plan-level star ratings for Part D – identifies plans with high incentive to improve MTM performance. Play 1
U.S. Census Bureau County Business Patterns (U.S.) United States HIGH Number of pharmacies per county by employee size – validates address and market density. Play 1
National Council for Prescription Drug Programs (NCPDP) Pharmacy Database (U.S.) United States HIGH Pharmacy NPI, address, and service codes – used for initial target list generation. Play 1
CMS Medicare Enrollment Dashboard (U.S.) United States HIGH County-level Medicare beneficiary counts – validates market size for Part D revenue estimation. Play 1
State Board of Pharmacy License Lookup (U.S.) United States HIGH Pharmacy license status, ownership, and disciplinary history – validates active provider status. Play 1
LinkedIn Sales Navigator (U.S.) United States MEDIUM Pharmacy owner/manager profiles, company size, and technology stack mentions (e.g., clinical platforms). Play 1
Better Business Bureau (BBB) Business Profiles (U.S.) United States MEDIUM Pharmacy business details, years in operation, and complaint history – helps prioritize established targets. Play 1
Google Maps / Places API (U.S.) United States MEDIUM Pharmacy location, hours, and user reviews – validates presence and community engagement. Play 1
CMS Quality Payment Program (QPP) Data (U.S.) United States HIGH MIPS scores and clinical quality measure performance for eligible clinicians – identifies high-value targets for clinical revenue improvement. Play 1